NDATOPICALCREAM
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
6/8 — Strong
VTAMA (tapinarof) by Merck & Co. is aryl hydrocarbon receptor agonists [moa]. Approved for aryl hydrocarbon receptor agonist [epc]. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VTAMA (tapinarof) is a topical cream formulation containing a small-molecule aryl hydrocarbon receptor (AhR) agonist approved by the FDA on May 23, 2022. It is indicated for the treatment of atopic dermatitis through a novel mechanism of action that activates the aryl hydrocarbon receptor, a pathway implicated in skin barrier function and immune regulation. Tapinarof represents a first-in-class approach to dermatological inflammation, offering an alternative to corticosteroids and calcineurin inhibitors. The product is currently in its peak commercial lifecycle stage as a Merck & Co. sponsored therapy.
$0.0BPart D
13.6 years to LOEMechanism of Action
Aryl Hydrocarbon Receptor Agonists
Pharmacologic Class:
Aryl Hydrocarbon Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Started Jun 2026
30 enrolled
Pancreatic Cancer ResectablePancreatic Cancer
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
Started Dec 2024
560 enrolled
Plaque Type Psorisis
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
Started Feb 2024
17 enrolled
Metastatic Colorectal Cancer
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Started Aug 2019
763 enrolled
Plaque Psoriasis
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
Started Jun 2019
515 enrolled
Plaque Psoriasis
Worked on VTAMA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.